133 results
8-K
EX-1.1
ABBV
Abbvie Inc
26 Feb 24
Other Events
5:08pm
list administered by OFAC, the State Department of the United States, the European Union or His Majesty’s Treasury (collectively, “Sanctions”) or (3
424B5
ABBV
Abbvie Inc
26 Feb 24
Prospectus supplement for primary offering
6:12am
and Mexico (collectively, “North America”), and in the European Union:
Condition
Principal Markets
Rheumatoid arthritis (moderate to severe)
North … America, European Union
Psoriatic arthritis
North America, European Union
Ankylosing spondylitis
North America, European Union
Adult Crohn’s disease
424B5
bhlaonu2ed3 uzqvtw0
21 Feb 24
Prospectus supplement for primary offering
8:39am
8-K
EX-99.1
hlx pgnv6rfnrnalxjl
2 Feb 24
AbbVie Reports Full-Year and Fourth-Quarter 2023 Financial Results
7:51am
8-K
EX-99.1
5p2xf1najejeyks
30 Nov 23
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
8:47am
8-K
EX-99.1
tq7di6mfjwp e7
27 Oct 23
AbbVie Reports Third-Quarter 2023 Financial Results
7:49am
8-K
EX-99.1
xlnxoa9fcce
27 Jul 23
AbbVie Reports Second-Quarter 2023 Financial Results
7:45am
8-K
EX-99.1
al1 txgdz3
27 Apr 23
AbbVie Reports First-Quarter 2023 Financial Results
7:36am